3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
2
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
2
Sarcoma
1
Myeloid
1
Conditions
Glioblastoma
6
Neuroblastoma
5
Central Nervous System Neoplasms
5
Gliosarcoma
4
Medulloblastoma
3
Glioma
3
Brain Neoplasms
3
Sarcoma
2
Rhabdoid Tumor
2
Recurrence
2
Pinealoma
2
Ependymoma
2
Sarcoma, Ewing
1
Rhabdomyosarcoma
1
Pyloric Stenosis, Hypertrophic
1
Osteosarcoma
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma
1
Neuroectodermal Tumors, Primitive
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms
1
Lymphoma
1
Leukemia
1
Histiocytosis, Langerhans-Cell
1
Carcinoma
1
Brainstem Glioma
1
Astrocytoma
1
Interventions
Temozolomide
26
Magnetic Resonance Spectroscopy
19
Etoposide
12
Cyclophosphamide
12
Radiotherapy
11
Bevacizumab
10
Filgrastim
9
Biopsy
8
Carboplatin
7
X-Rays
6
Thiotepa
6
Specimen Handling
6
Phantoms, Imaging
6
Cisplatin
6
Carmustine
6
Nuclear Medicine Department, Hospital
5
Nivolumab
5
Irinotecan
5
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
5
sargramostim
4
Radiation
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
olaparib
3
etoposide phosphate
3
Vincristine
3
Surveys and Questionnaires
3
Lapatinib
3
Gadolinium DTPA
3
Azacitidine
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Ependymoma
×
Celecoxib
×
CNS
×
Clear all
NCT02574728
2026-03-02
AflacST1502
Emory University
Phase 2
Active not recruiting
46 enrolled
NCT01356290
2026-02-23
MEMMAT
Medical University of Vienna
Phase 2
Recruiting
232 enrolled